![Peter Kellogg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Kellogg
Direttore Finanziario/CFO presso
RECEPTOS INC
Patrimonio netto: 342 105 $ in data 30/06/2026
Profilo
Peter N.
Kellogg is currently an Independent Director at Alnylam Pharmaceuticals, Inc. since 2023.
Mr. Kellogg is also a Director at Idorsia Pharmaceuticals Ltd. and serves as Chief Financial Officer & Executive Vice President at Receptos LLC.
Formerly, Mr. Kellogg was an Independent Director at Yield10 Bioscience, Inc. from 2011 to 2020.
Mr. Kellogg was a Non-Executive Director at Idorsia Ltd. from 2021 to 2024.
Mr. Kellogg was a Director at Juno Therapeutics, Inc. Mr. Kellogg was Chief Financial Officer & Executive Vice President at Biogen MA, Inc. in 2003.
Mr. Kellogg was Chief Financial Officer & Executive Vice President at Merck & Co., Inc. from 2007 to 2014.
Mr. Kellogg was Senior Vice President-eCommerce at PepsiCo, Inc. in 2000.
Mr. Kellogg was Chief Financial Officer & Executive Vice President at Schering-Plough Corp.
in 2009.
Mr. Kellogg was Chief Financial Officer & Executive Vice President at Biogen, Inc. from 2003 to 2007.
Mr. Kellogg was Principal at Pepsi-Cola International Ltd. (New York).
Mr. Kellogg was Principal at Pepsi-Cola North America.
Mr. Kellogg was Senior Vice President at PepsiCo Food International.
Mr. Kellogg was Executive Vice President at Biogen Idec New Ventures, Inc. from 2000 to 2007.
Mr. Kellogg was Chief Financial Officer & Executive VP-Finance at Biogen Idec, Inc. (North Carolina) from 2003 to 2007.
Mr. Kellogg was Chief Financial Officer & Senior Vice President at Frito-Lay International from 1998 to 2000.
Mr. Kellogg was Chief Financial Officer & Executive Vice President at Merck Sharp & Dohme Corp.
from 2007 to 2009.
Mr. Kellogg was Chief Corporate Strategy Officer & Executive VP at Celgene Corp.
from 2018 to 2019.
Education includes an undergraduate degree from Princeton University in 1978 and an MBA from The Wharton School of the University of Pennsylvania in 1982.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 20/05/2026 | 775 ( 0% ) | 233 298 $ | 30/06/2026 | |
IDORSIA LTD. 0,01% | 31/12/2024 | 12.785 ( 0,01% ) | 108 807 $ | 30/06/2026 |
Posizioni attive di Peter Kellogg
| Società | Posizione | Inizio |
|---|---|---|
| RECEPTOS INC | Direttore Finanziario/CFO | - |
| ALNYLAM PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 07/03/2023 |
Idorsia Pharmaceuticals Ltd.
 Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceuticals | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Peter Kellogg
| Società | Posizione | Fine |
|---|---|---|
| IDORSIA LTD | Direttore/Membro del Consiglio | 13/06/2024 |
| YIELD10 BIOSCIENCE, INC. | Direttore/Membro del Consiglio | 11/02/2020 |
| CELGENE | Direttore Finanziario/CFO | 01/08/2018 |
| MERCK & CO., INC. | Direttore Finanziario/CFO | 23/04/2014 |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical & health care products | Direttore Finanziario/CFO | 03/11/2009 |
Formazione di Peter Kellogg
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
85
Relazioni di 1° grado
21
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 21 |
|---|---|
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Develops and manufactures drugs related to immunology, neurobiology and oncology | Health Technology |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
PepsiCo, Inc.
 PepsiCo, Inc. Food: Specialty/CandyConsumer Non-Durables Makes, markets, distributes and sells beverages & convenient food products | Consumer Non-Durables |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical & health care products | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Yield10 Bioscience, Inc.
 Yield10 Bioscience, Inc. Chemicals: AgriculturalProcess Industries Operates as an agricultural bioscience company that focused on commercializing sustainable products | Process Industries |
Receptos LLC
 Receptos LLC Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes therapeutics in immune disease | Health Technology |
Pepsi-Cola International Ltd. (New York)
 Pepsi-Cola International Ltd. (New York) Beverages: Non-AlcoholicConsumer Non-Durables Makes soft drinks and snack foods | Consumer Non-Durables |
Pepsi-Cola North America
 Pepsi-Cola North America Beverages: Non-AlcoholicConsumer Non-Durables Manufactures and markets beverage products | Consumer Non-Durables |
PepsiCo Food International
 PepsiCo Food International Beverages: Non-AlcoholicConsumer Non-Durables Carbonated beverage company | Consumer Non-Durables |
Alnylam Pharmaceuticals, Inc.
 Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Princeton University
 Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Biogen Idec New Ventures' strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. Their specific areas of interest are companies in Biogen Idec's current therapeutic areas of neurology, oncology and immunology/inflammation, but they also seek opportunities outside these areas that fit their strategies for longer-term growth. The firm invests at all stages of development; most of their investments are in early-stage companies. They also look for investment opportunities where they can leverage their parent's resources and scientific and development expertise to support these investments. | Finance |
Biogen Idec, Inc. (North Carolina)
 Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Frito-Lay International | |
Merck Sharp & Dohme Corp.
 Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Health Technology |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company to treat cancer, HIV and cardiovascular diseases | Health Technology |
Idorsia Ltd.
 Idorsia Ltd. Pharmaceuticals: MajorHealth Technology Engages in the discovery, development and commercialization of medicines for unmet medical needs | Health Technology |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceuticals | Health Technology |
